Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
190lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Learning paths
Pick a track — progress rings update as you complete lessons.
Guided curriculum
Research deep dives (after the basics)
Once you understand fundamentals, use these modules to follow trial readouts, mechanisms, and specialty peptides in more detail.
Who it's for: Intermediate learners who completed Foundations + Safety.
Unit 1
Module 1 — Trial literacy
Read outcomes without drowning in jargon.
You'll be able to
- ✓Interpret phase labels and endpoints
- ✓Compare GLP-1 trial designs
- ✓Separate surrogate markers from patient outcomes
55 lessons in Research & Science
7mResearchAdvanced
KLOW Peptide Blend: What's In It, How to Use It, and When to Pin Separately
KLOW combines BPC-157, TB-500, and GHK-Cu in a single vial. Here's how it works, what to expect, and when separate pins are the better call.
8mResearchAdvanced
FDA Peptide Compounding Review: What the Seven-Peptide Debate Means for Buyers and Clinics
Regulation does not settle the peptide debate by itself. It forces clearer questions about sourcing, safety, evidence, and who is responsible when claims move faster than data.
8mResearchAdvanced
MOTS-c and Human Cell Repair: Why Metabolic Signaling Can Come With a Tradeoff
MOTS-c is not just a mitochondrial story. In human cells, the same signal that turns on metabolism may also dampen repair, which makes context matter.
8mResearchAdvanced
MOTS-c and Human Cell Repair: Why Metabolic Signaling Can Come With a Tradeoff
MOTS-c is not just a mitochondrial story. In human cells, the same signal that turns on metabolism may also dampen repair, which makes context matter.
9mResearchAdvanced
Retatrutide and Body Composition: Why the Real Story Is Adherence, Not Just Scale Weight
The best metabolic tools do more than move the scale. They change how easy it is to follow the plan on day 3, day 30, and day 300.
10mResearchAdvanced
Therapeutic Peptides in Orthopaedics: What the New Review Actually Means for Injury Recovery
Orthopaedics is paying closer attention to peptides because the field keeps running into the same problem: recovery is biology, but biology still needs evidence before it becomes a protocol.
9mResearchAdvanced
GLP-1s and Muscle Health: What the Latest Meta-Analysis Means for Body Recomposition
GLP-1 weight loss is not the same as automatic muscle loss. The real story depends on protein, resistance training, and tracking.
9mResearchAdvanced
Tesamorelin and Liver Fat: Why the TESA-LIVER Trial Matters
Tesamorelin has one of the cleanest human-data stories in the peptide space. The new liver fat trial matters because it asks whether that signal extends into fatty liver disease.
8mResearchAdvanced
Retatrutide and Food Noise: Why Appetite Control Changes Adherence
The scale is only part of the story. Retatrutide's biggest advantage may be how it quiets food noise and makes adherence easier to sustain.
8mResearchAdvanced
GLP-1 Muscle Preservation: How to Keep Lean Mass While Losing Fat in 2026
GLP-1s can drive impressive weight loss, but the real win is losing fat without giving up strength. This guide shows how to protect lean mass while appetite is down.
8mResearchAdvanced
Retatrutide and Visceral Fat: Why the Scale Misses the Real Signal
Scale weight is noisy. If you are using retatrutide, waist trend, body composition, protein intake, and strength matter more than a single weigh-in.
8mResearchAdvanced
Peptide Clinical Evidence in 2026: How to Separate Signal from Hype
Peptide research is moving fast. Here is how to read the evidence before turning a headline, mechanism, or social post into a protocol.
8mResearchAdvanced
BPC-157 and Ischemia-Reperfusion Injury: What the 2026 Rat Study Found
New 2026 data puts BPC-157 into a sharper recovery frame: oxidative stress, inflammation, apoptosis, angiogenesis, and the limits of animal evidence.
8mResearchAdvanced
GLP-1s and Macular Degeneration: What the Eye Studies Say
GLP-1 research is moving beyond weight loss. Recent ophthalmology studies suggest possible links with age-related macular degeneration, but the signals are mixed and need careful interpretation.
8mResearchAdvanced
MOTS-c and Atrial Fibrillation: What the 2026 Study Suggests
MOTS-c is moving beyond the generic energy peptide conversation. New 2026 research connects mitochondrial-derived peptides with atrial fibrosis, inflammation, and heart rhythm biology.
7mResearchAdvanced
GLP-1s Before Bariatric Surgery: What the 2026 Evidence Says
GLP-1 peptides are changing the bariatric surgery conversation. The practical lesson is not self-managing around surgery. It is better tracking, clearer handoffs, and coordinated medical planning.
8mResearchAdvanced
GHK-Cu Topical Gel Trial: What Wound Healing Data Could Show
GHK-Cu is moving beyond skin-care hype into a controlled wound-healing study. Here is how to read the Phase 2 trial without overclaiming the result.
8mResearchAdvanced
MOTS-c and Mitochondrial Metabolism: What the 2026 Human Trial Is Testing
MOTS-c is one of the most interesting mitochondrial peptides in 2026 because the question is finally shifting from mechanism to human outcomes.
8mResearchAdvanced
Retatrutide TRIUMPH-1 Phase 3 Results: How to Track the 28.3% Weight Loss Data
The new TRIUMPH-1 readout gives retatrutide users a clearer dose-response map: 4 mg, 9 mg, and 12 mg all worked, but the tolerability tradeoffs matter.
7mResearchAdvanced
Peptide Regulation and Sourcing Safety in 2026
The biggest peptide trend in 2026 may not be a molecule. It may be oversight, sourcing quality, and the ability to separate evidence from marketing.
7mResearchAdvanced
GHK-Cu: Beyond Anti-Aging — The Regenerative Peptide Rewriting Wound Care
A 2025 Biomaterials Research paper shows GHK-Cu hydrogel achieving full infected wound healing — antibacterial, anti-inflammatory, and neovascularization effects. Here's what the mechanism actually means for regenerative protocols.
8mResearchAdvanced
BPC-157 and GLP-1 Side Effects: What the Research Really Shows
GLP-1 receptor agonists cause nausea in up to 44% of users and it is the top reason for discontinuation. Here is what the research shows about BPC-157 as a potential gut protectant, and where the evidence stops.
7mResearchAdvanced
The Multi-Peptide Stack: What 2026 Peer-Reviewed Science Actually Shows
Two 2026 peer-reviewed reviews in Sports Medicine and JAAOS now formally catalog BPC-157, TB-500, GHK-Cu, CJC-1295, and Ipamorelin stacks. Here is what the science actually shows — and where the gaps still are.
8mResearchAdvanced
Tirzepatide vs. Semaglutide: What the 2026 Data Actually Shows
New head-to-head trials and real-world data from 2025-2026 reveal tirzepatide and semaglutide are not equivalent - they produce meaningfully different outcomes depending on your goals.
7mResearchAdvanced
BPC-157 Hits a Milestone: The First Controlled Human Trial Is Now Recruiting
After 30+ years of animal research and 212 preclinical studies, BPC-157 has entered its first Phase 2 human trial. Here's what it will test, what it won't prove, and what to track.
7mResearchAdvanced
Injectable Peptide Safety Checklist: What Doctors Want Patients to Know in 2026
AMA and FDA updates make one thing clear: peptide interest is moving faster than human evidence, dosing standards, and product-quality controls. Use this checklist before trusting a vial.
9mResearchAdvanced
SLU-PP-332: The ERRα Agonist That Gives You the Benefits of Exercise in a Vial
SLU-PP-332 is a small-molecule ERRα agonist with remarkable endurance, fat oxidation, and mitochondrial benefits. Here's the complete guide to what it does, who it's for, and how to use it.
8mResearchAdvanced
Selank and Semax: The Complete Protocol for Calm Focus and Cognitive Enhancement
Selank and Semax are two of the most powerful intranasal nootropic peptides available. Here's how they work, how they differ, and the best protocols for using them separately or stacked.
8mResearchAdvanced
Tesamorelin and Visceral Fat: What the 2026 Meta-Analysis Shows
Tesamorelin has one of the stronger human-data profiles in the peptide space. A 2026 meta-analysis helps clarify what it improves, what it does not, and how to track the signal honestly.
7mResearchAdvanced
GLP-1 Lean Mass Loss: What 2026 Data Shows
A new 2026 meta-analysis puts real numbers on lean mass change during semaglutide, tirzepatide, and liraglutide weight loss. The practical takeaway is not panic. It is better tracking.
8mResearchAdvanced
BPC-157 Human Hamstring Trial: Why This Study Matters
BPC-157 finally has a registered human sports-injury study. The signal is important, but it is not proof yet. Here is how to read the trial without the hype.
8mResearchAdvanced
Wellness Peptides and the Evidence Gap: What ECRI and ISMP Warned
A new ECRI and ISMP warning says popular wellness peptides are being marketed faster than the evidence can support. Here is how to separate compound science from product risk.
8mResearchAdvanced
Health Canada Peptide Warning: What Buyers Should Know
Health Canada's 2026 public advisory names unauthorized injectable peptides sold online and explains why product quality, legal status, and medical supervision matter.
8mResearchAdvanced
Retatrutide Trials in 2026: Back Pain, Liver, Heart, and Muscle Signals to Watch
Retatrutide is no longer just a weight-loss headline. Current 2026 trial records show researchers testing broader questions: pain, liver disease, cardiorenal risk, dose escalation, and lean-mass preservation.
8mResearchAdvanced
Peptide Therapy for Sports Injuries: What 2026 Evidence Really Shows
A new sports medicine review puts injury-recovery peptides in context. Some mechanisms are promising, but human evidence, safety data, and regulatory status still matter.
8mResearchAdvanced
GLP-1 Nutrition Strategy: Protein, Muscle, and Labs
New 2026 reviews show a nutrition gap in GLP-1 and incretin therapy research. Here is how to protect protein intake, lean mass, hydration, and labs while appetite is suppressed.
7mResearchAdvanced
Efsubaglutide Alfa SUPER1 Trial: What the New GLP-1 Data Shows
Efsubaglutide alfa is a long-acting GLP-1 receptor agonist with new human trial data in drug-naive type 2 diabetes. Here is what the SUPER1 results actually show.
9mResearchAdvanced
Retatrutide TRIUMPH-4: 28.7% Weight Loss and Osteoarthritis Relief in One Peptide
The TRIUMPH-4 trial delivers groundbreaking dual benefits: 28.7% body weight reduction plus significant osteoarthritis pain relief. Retatrutide's triple mechanism may solve two problems simultaneously.
9mResearchAdvanced
BPC-157 and TB-500 for Torn Meniscus Recovery: Real Case Report
A torn meniscus and Baker cyst — both resolved without surgery. This Reddit case report shows what BPC-157 and TB-500 can do for knee injuries. But the clinical picture is more complicated than a success story.
7mResearchAdvanced
Retatrutide Trial Participant Hit 31% Total Body Weight Loss: What the Number Actually Means
31% body weight loss in a trial participant. Not an average — an individual result. But when 39.4% of Phase 3 participants on the 12mg dose hit the same milestone, the outlier becomes a pattern.
9mResearchAdvanced
GLP-1 Food Noise: Why It Comes Back After Stopping and What Actually Helps
Food noise — that constant mental chatter about food — often comes back after stopping GLP-1 peptides. Here's the science of why, and what actually helps: maintenance strategies, stacking options, and realistic expectations.
9mResearchAdvanced
Retatrutide Phase 3 Results: 28.7% Weight Loss Sets New Standard
New Phase 3 data shows Retatrutide nearly doubled the weight loss results of current GLP-1 drugs without hitting a plateau.
8mResearchAdvanced
FDA Warning Letters Signal a New Era for Peptide Buyers
Seven FDA warning letters in April 2026 show regulators are paying closer attention to online peptide sellers, especially research-use-only marketing that looks like consumer health claims.
9mResearchAdvanced
Peptides for Psoriasis and Autoimmune Skin Conditions: What the Research Shows
Psoriasis affects 125 million people worldwide. While peptides aren't a cure, emerging research suggests certain compounds may help calm inflammation and support skin repair. Here's what the science says.
9mResearchAdvanced
GLP-1 for Weight Loss Without Diabetes: What the 2026 Systematic Review Found
You don't need to have diabetes to benefit from GLP-1 therapy. A comprehensive 2026 systematic review confirms what the peptide community has known for years — and the results are striking.
9mResearchAdvanced
RFK Jr., the FDA, and BPC-157: What the 2026 Regulatory Reversal Means for Peptide Access
After years of FDA crackdowns on research peptides, a significant regulatory reversal in 2026 has changed the landscape for BPC-157, TB-500, and MOTS-C. Here's what actually happened and what it means for you.
9mResearchAdvanced
Why Your Weight Isn't Moving on Retatrutide (And What to Do About It)
Hitting a plateau on Retatrutide is common and usually temporary. Here's the science behind GLP-1 stalls and the practical steps to break through them.
9mResearchAdvanced
BPC-157 Human Trial: 87.5% of Knee Pain Patients Report Significant Relief at 6–12 Months
87.5% of patients with chronic knee pain reported significant relief after BPC-157 treatment at the 6–12 month follow-up. Here's a breakdown of the human trial data, the dosing protocol used, and why this peptide is getting serious clinical attention.
9mResearchAdvanced
Cerebrolysin: Dosing, Reconstitution, and What to Expect
Cerebrolysin is a brain-derived peptide mixture used for neuroprotection and cognitive enhancement. Here's what the research says, how to reconstitute it, and what real protocols look like.
8mResearchAdvanced
Dihexa: The Most Potent Nootropic Peptide You've Probably Never Heard Of
A complete breakdown of Dihexa — mechanism of action, dosing, what users actually report, and how it compares to Semax and Selank for cognitive enhancement.
9mResearchAdvanced
Retatrutide TRIUMPH-4 Phase 3 Trial: 28.7% Body Weight Reduction Confirmed
Phase 3 data is in: retatrutide produced an average 28.7% body weight reduction — roughly 71 lbs — in the TRIUMPH-4 trial. Here's what the numbers mean and how the triple agonist mechanism drives these results.
10mResearchAdvanced
Retatrutide TRANSCEND Trial: What the Phase 3 Data Actually Shows
TRANSCEND confirmed retatrutide as the most effective GLP-1 class compound tested in late-stage trials. 16.8% mean body weight reduction and a 2.0-point A1C drop in 40 weeks — here's what the full data shows.
9mResearchAdvanced
FDA Peptide Reclassification 2026: BPC-157, GHK-Cu, and MOTS-C Return to Legal Compounding
14 peptides including BPC-157, GHK-Cu, and MOTS-C are returning to legal compounding under FDA oversight. What changed, what it means for access, and what to expect next.
9mResearchAdvanced
Retatrutide 2-Year Weight Loss Durability: What the Latest Data Shows
Retatrutide is showing remarkable 2-year durability for weight loss. Here's what the science says and what it means for your protocol.
10mResearchAdvanced
How to Read Peptide Research: Understanding Studies and Claims
Develop the skills to critically evaluate peptide research and distinguish solid science from marketing hype.
Also available at /blog for legacy links.